Literature DB >> 17850582

Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE.

B Bielecki1, A Mazurek, P Wolinski, A Glabinski.   

Abstract

Chemokines and their receptors are important players in organism homeostasis, development and immune response to inflammatory stimuli. It has been recently confirmed that they are also involved in the development of several autoimmune diseases. In this study, we analysed the expression of two recently identified CC chemokine receptors, CCR7 and CCR8, in the central nervous system (CNS) and in peripheral tissues during chronic relapsing experimental autoimmune encephalomyelitis (ChREAE) -- an animal model of the human demyelinating disease multiple sclerosis (MS). We observed upregulation of both chemokine receptors in the CNS during the first and second attacks of ChREAE, whereas disease remission was characterized by a lower expression of those receptors. An analysis of the kinetics of CCR7 and CCR8 expression in the CNS during the first attack of the disease showed a constant increase in the first few days after the onset of clinical signs. This expression correlated with the clinical severity of ChREAE. CCR7-positive mononuclear cells were detected mostly in perivascular inflammatory cuffs in the CNS. In peripheral tissues (the spleen and kidneys) expression of both receptors was not upregulated during active ChREAE. These findings suggest that CCR7 and CCR8 may play a significant role in the pathogenesis of EAE and probably MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850582     DOI: 10.1111/j.1365-3083.2007.01954.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Central Nervous System and Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple Sclerosis.

Authors:  Bartosz Bielecki; Izabela Jatczak-Pawlik; Pawel Wolinski; Andrzej Bednarek; Andrzej Glabinski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-05-10       Impact factor: 4.291

3.  Prophylactic Chronic Zinc Administration Increases Neuroinflammation in a Hypoxia-Ischemia Model.

Authors:  Constantino Tomas-Sanchez; Victor Manuel Blanco-Alvarez; Juan Antonio Gonzalez-Barrios; Daniel Martinez-Fong; Guadalupe Garcia-Robles; Guadalupe Soto-Rodriguez; Eduardo Brambila; Maricela Torres-Soto; Alejandro Gonzalez-Vazquez; Ana Karina Aguilar-Peralta; José-Luis Garate-Morales; Luis-Angel Aguilar-Carrasco; Daniel I Limón; Jorge Cebada; Bertha Alicia Leon-Chavez
Journal:  J Immunol Res       Date:  2016-08-18       Impact factor: 4.818

Review 4.  Lymphoid chemokines in chronic neuroinflammation.

Authors:  Francesca Aloisi; Sandra Columba-Cabezas; Diego Franciotta; Barbara Rosicarelli; Roberta Magliozzi; Richard Reynolds; Elena Ambrosini; Eliana Coccia; Marco Salvetti; Barbara Serafini
Journal:  J Neuroimmunol       Date:  2008-06-09       Impact factor: 3.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.